Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial

Nina Magnolo; Thomas Jaenicke; Athanasios Tsianakas; Wolfgang Czech; Diamant Thaçi; Andreas Pinter; Delphine Kerob; Samir Salah; Thomas A. Luger

doi:10.1111/jdv.18949

Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial

Nina Magnolo, Thomas Jaenicke, Athanasios Tsianakas, Wolfgang Czech, Diamant Thaçi, Andreas Pinter, Delphine Kerob, Samir Salah, Thomas A. Luger^*

^*Korrespondierende/r Autor/-in für diese Arbeit

Institut für Entzündungsmedizin

14 Zitate (Scopus)

Abstract

Background: Moderate to severe AD can be successfully managed by systemic treatments. Current guidelines also recommend emollients or emollients ‘plus’ and eudermic cleansers for all AD patients to improve the skin barrier and provide anti-irritant and anti-pruritic effects. Objectives: To investigate the efficacy of skin care (in addition to systemic treatment) with an Emollient ‘plus’ balm designed to improve the skin barrier and skin microbiome plus a corresponding syndet compared to usual commercial emollients and cleansers. Methods: In a randomized controlled multicenter study, patients with moderate to severe AD (Severity scoring of atopic dermatitis [SCORAD] score ≥ 40) receiving systemic treatment (cyclosporin A, dupilumab or a Janus kinase inhibitor) were randomized 1:1 to apply twice daily for 10 weeks Emollient ‘plus’ after pre-cleaning with the syndet (Emollient ‘plus’ group) or to continue with their usual emollient and cleanser (Control group). Assessments included SCORAD, pruritus on a Visual Analog Scale, Dermatology quality of life questionnaire (DLQI), efficacy and tolerance questionnaires. Results: Included were 57 patients with mean age of 38 years (range 19–70 years). The mean amount of emollient used after 10 weeks was 447.3 g (range 29–1099 g) and 613.2 g (range 97–2565 g) for the Emollient ‘plus’ versus the Control, respectively (p = 0.0277). After 10 weeks, subjects in the Emollient ‘plus’ had a significantly greater reduction in current pruritus (p = 0.0277) and a greater reduction in some DLQI items compared to the Control group. Conclusions: In patients with moderate to severe AD receiving systemic treatment, the Emollient ‘plus’ regimen significantly improved pruritus and quality of life items compared to the control, while using 23% less product over a 10-week period. These results stress the importance of daily use of emollients, especially emollients ‘plus’ to improve signs, symptoms and quality of life in patients with AD.

Originalsprache	Englisch
Zeitschrift	Journal of the European Academy of Dermatology and Venereology
Jahrgang	37
Ausgabenummer	S5
Seiten (von - bis)	18-26
Seitenumfang	9
ISSN	0926-9959
DOIs	https://doi.org/10.1111/jdv.18949
Publikationsstatus	Veröffentlicht - 06.2023

Fördermittel

DK and SS are employees of La Roche‐Posay. NM: Honoraria for participation on advisory boards, as a speaker and/or for consultancy from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer and UCB Pharma. Investigator in the presented trial. TJ: Senior Scientist with IUF, has participated as Investigator and Monitor in clinical trials sponsored by Spirig Pharma, Vanda Pharmaceuticals, Sumitomo, and Stada. AT, WC: Investigator in the presented trial. DT: Has received honoraria as an advisor, speaker and/or investigator from AbbVie, Almirall, Amgen, Biogen‐Idec, Boehringer Ingelheim, Bristol‐Myers Squibb, Eli Lilly, Galapagos, Galderma, Janssen‐Cilag, LEO Pharma, Novartis, Pfizer, Regeneron, La Roche‐Posay, Samsung, Sanofi, and UCB. AP: Investigator in the presented trial, has served as an advisor and/or paid speaker for and/or participated in clinical trials sponsored by: AbbVie, Almirall‐Hermal, Amgen, Biogen Idec, Biontec, Boehringer‐Ingelheim, Celgene, Celltrion, GSK, Eli‐Lilly, Eva Pharma, Galderma, Hexal, Janssen, Klinge Pharma, LEO‐Pharma, MC2, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Sanofi‐Genzyme, Schering‐Plough, UCB Pharma and Zuellig Pharma. TAL: Investigator in the present trial and has participated as Principal Investigator in clinical trials, advisory boards and has given lectures, sponsored by Novartis, Lilly, La Roche Posay, Pfizer, Janssen, and Sanofi. He has received consultancy/speaker honoraria from Novartis, Abbvie, Galderma, La Roche Posay, Meda Pharma S.p.A. (a Viatris company), Janssen, and Sanofi, and has acted as a scientific Advisory Board member for Abbvie, Celgene, La Roche Posay, Janssen, Pfizer, Menlo, Meda Pharma S.p.A. (a Viatris company), Galderma, Symrise, and Lilly. He has received research grants from: Celgene, Janssen‐Cilag, Leo, Meda Pharma S.p.A. (a Viatris company) and Pfizer. The study and writing/editorial support were funded by La Roche‐Posay.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)
Zentren: Center for Research on Inflammation of the Skin (CRIS)

DFG-Fachsystematik

2.22-19 Dermatologie

Dokumente

10.1111/jdv.18949

Weitere Links

Link to publication in Scopus

Zitieren

Magnolo, N., Jaenicke, T., Tsianakas, A., Czech, W., Thaçi, D., Pinter, A., Kerob, D., Salah, S., & Luger, T. A. (2023). Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial. Journal of the European Academy of Dermatology and Venereology, 37(S5), 18-26. https://doi.org/10.1111/jdv.18949

@article{aa880fa2df214064bb6147247c2e9384,

title = "Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial",

abstract = "Background: Moderate to severe AD can be successfully managed by systemic treatments. Current guidelines also recommend emollients or emollients {\textquoteleft}plus{\textquoteright} and eudermic cleansers for all AD patients to improve the skin barrier and provide anti-irritant and anti-pruritic effects. Objectives: To investigate the efficacy of skin care (in addition to systemic treatment) with an Emollient {\textquoteleft}plus{\textquoteright} balm designed to improve the skin barrier and skin microbiome plus a corresponding syndet compared to usual commercial emollients and cleansers. Methods: In a randomized controlled multicenter study, patients with moderate to severe AD (Severity scoring of atopic dermatitis [SCORAD] score ≥ 40) receiving systemic treatment (cyclosporin A, dupilumab or a Janus kinase inhibitor) were randomized 1:1 to apply twice daily for 10 weeks Emollient {\textquoteleft}plus{\textquoteright} after pre-cleaning with the syndet (Emollient {\textquoteleft}plus{\textquoteright} group) or to continue with their usual emollient and cleanser (Control group). Assessments included SCORAD, pruritus on a Visual Analog Scale, Dermatology quality of life questionnaire (DLQI), efficacy and tolerance questionnaires. Results: Included were 57 patients with mean age of 38 years (range 19–70 years). The mean amount of emollient used after 10 weeks was 447.3 g (range 29–1099 g) and 613.2 g (range 97–2565 g) for the Emollient {\textquoteleft}plus{\textquoteright} versus the Control, respectively (p = 0.0277). After 10 weeks, subjects in the Emollient {\textquoteleft}plus{\textquoteright} had a significantly greater reduction in current pruritus (p = 0.0277) and a greater reduction in some DLQI items compared to the Control group. Conclusions: In patients with moderate to severe AD receiving systemic treatment, the Emollient {\textquoteleft}plus{\textquoteright} regimen significantly improved pruritus and quality of life items compared to the control, while using 23\% less product over a 10-week period. These results stress the importance of daily use of emollients, especially emollients {\textquoteleft}plus{\textquoteright} to improve signs, symptoms and quality of life in patients with AD.",

author = "Nina Magnolo and Thomas Jaenicke and Athanasios Tsianakas and Wolfgang Czech and Diamant Tha{\c c}i and Andreas Pinter and Delphine Kerob and Samir Salah and Luger, \{Thomas A.\}",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley \& Sons Ltd on behalf of European Academy of Dermatology and Venereology.",

year = "2023",

month = jun,

doi = "10.1111/jdv.18949",

language = "English",

volume = "37",

pages = "18--26",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "John Wiley and Sons Inc",

number = "S5",

}

Magnolo, N, Jaenicke, T, Tsianakas, A, Czech, W, Thaçi, D, Pinter, A, Kerob, D, Salah, S & Luger, TA 2023, 'Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial', Journal of the European Academy of Dermatology and Venereology, Jg. 37, Nr. S5, S. 18-26. https://doi.org/10.1111/jdv.18949

Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial. / Magnolo, Nina; Jaenicke, Thomas; Tsianakas, Athanasios et al.
in: Journal of the European Academy of Dermatology and Venereology, Jahrgang 37, Nr. S5, 06.2023, S. 18-26.

Publikation: Beiträge in Fachzeitschriften › Zeitschriftenaufsätze › Forschung › Begutachtung

TY - JOUR

T1 - Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment

T2 - A randomized controlled trial

AU - Magnolo, Nina

AU - Jaenicke, Thomas

AU - Tsianakas, Athanasios

AU - Czech, Wolfgang

AU - Thaçi, Diamant

AU - Pinter, Andreas

AU - Kerob, Delphine

AU - Salah, Samir

AU - Luger, Thomas A.

N1 - Publisher Copyright: © 2023 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

PY - 2023/6

Y1 - 2023/6

N2 - Background: Moderate to severe AD can be successfully managed by systemic treatments. Current guidelines also recommend emollients or emollients ‘plus’ and eudermic cleansers for all AD patients to improve the skin barrier and provide anti-irritant and anti-pruritic effects. Objectives: To investigate the efficacy of skin care (in addition to systemic treatment) with an Emollient ‘plus’ balm designed to improve the skin barrier and skin microbiome plus a corresponding syndet compared to usual commercial emollients and cleansers. Methods: In a randomized controlled multicenter study, patients with moderate to severe AD (Severity scoring of atopic dermatitis [SCORAD] score ≥ 40) receiving systemic treatment (cyclosporin A, dupilumab or a Janus kinase inhibitor) were randomized 1:1 to apply twice daily for 10 weeks Emollient ‘plus’ after pre-cleaning with the syndet (Emollient ‘plus’ group) or to continue with their usual emollient and cleanser (Control group). Assessments included SCORAD, pruritus on a Visual Analog Scale, Dermatology quality of life questionnaire (DLQI), efficacy and tolerance questionnaires. Results: Included were 57 patients with mean age of 38 years (range 19–70 years). The mean amount of emollient used after 10 weeks was 447.3 g (range 29–1099 g) and 613.2 g (range 97–2565 g) for the Emollient ‘plus’ versus the Control, respectively (p = 0.0277). After 10 weeks, subjects in the Emollient ‘plus’ had a significantly greater reduction in current pruritus (p = 0.0277) and a greater reduction in some DLQI items compared to the Control group. Conclusions: In patients with moderate to severe AD receiving systemic treatment, the Emollient ‘plus’ regimen significantly improved pruritus and quality of life items compared to the control, while using 23% less product over a 10-week period. These results stress the importance of daily use of emollients, especially emollients ‘plus’ to improve signs, symptoms and quality of life in patients with AD.

AB - Background: Moderate to severe AD can be successfully managed by systemic treatments. Current guidelines also recommend emollients or emollients ‘plus’ and eudermic cleansers for all AD patients to improve the skin barrier and provide anti-irritant and anti-pruritic effects. Objectives: To investigate the efficacy of skin care (in addition to systemic treatment) with an Emollient ‘plus’ balm designed to improve the skin barrier and skin microbiome plus a corresponding syndet compared to usual commercial emollients and cleansers. Methods: In a randomized controlled multicenter study, patients with moderate to severe AD (Severity scoring of atopic dermatitis [SCORAD] score ≥ 40) receiving systemic treatment (cyclosporin A, dupilumab or a Janus kinase inhibitor) were randomized 1:1 to apply twice daily for 10 weeks Emollient ‘plus’ after pre-cleaning with the syndet (Emollient ‘plus’ group) or to continue with their usual emollient and cleanser (Control group). Assessments included SCORAD, pruritus on a Visual Analog Scale, Dermatology quality of life questionnaire (DLQI), efficacy and tolerance questionnaires. Results: Included were 57 patients with mean age of 38 years (range 19–70 years). The mean amount of emollient used after 10 weeks was 447.3 g (range 29–1099 g) and 613.2 g (range 97–2565 g) for the Emollient ‘plus’ versus the Control, respectively (p = 0.0277). After 10 weeks, subjects in the Emollient ‘plus’ had a significantly greater reduction in current pruritus (p = 0.0277) and a greater reduction in some DLQI items compared to the Control group. Conclusions: In patients with moderate to severe AD receiving systemic treatment, the Emollient ‘plus’ regimen significantly improved pruritus and quality of life items compared to the control, while using 23% less product over a 10-week period. These results stress the importance of daily use of emollients, especially emollients ‘plus’ to improve signs, symptoms and quality of life in patients with AD.

UR - https://www.scopus.com/pages/publications/85153503949

U2 - 10.1111/jdv.18949

DO - 10.1111/jdv.18949

M3 - Journal articles

C2 - 37092275

AN - SCOPUS:85153503949

SN - 0926-9959

VL - 37

SP - 18

EP - 26

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - S5

ER -

Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial

Abstract

Fördermittel

UN SDGs

Strategische Forschungsbereiche und Zentren

DFG-Fachsystematik

Dokumente

Weitere Links

Fingerprint

Zitieren